XML 56 R91.htm IDEA: XBRL DOCUMENT v3.20.1
Subsequent events (Details) - Genentech Collaboration Agreement - Subsequent events
$ in Millions
Feb. 21, 2020
USD ($)
Subsequent events  
Number of Potential development candidates 4
Number of immuno oncology targets 2
Additional number of immuno oncology targets 2
Expansion Fee $ 10.0
Upfront payment fee 30.0
Regulatory, and initial commercialization milestones, payments receivable 200.0
Sales milestone payments, receivable $ 200.0
Royalty payable term from first commercial milestone 10 years
Minimum  
Subsequent events  
Success-based milestone payments per collaboration program $ 10.0
Maximum  
Subsequent events  
Success-based milestone payments per collaboration program $ 12.0